生产企业：Lobe Sciences Ltd.
L-130 (Conjugated Psilocin) is Lobe Sciences Ltd.'s patented lead CNS drug candidate: a patented salt of psilocin that delivers the active moiety directly rather than as a prodrug. It is designed for low-dose daily oral outpatient dosing with a more predictable psilocin exposure profile than conventional psilocybin, initially targeting cluster headache, with co-development in PTSD, substance use disorder and generalized anxiety disorder.
L-130 (Conjugated Psilocin) is Lobe Sciences Ltd.'s patented lead CNS drug candidate: a patented salt of psilocin that delivers the active moiety directly rather than as a prodrug. It is designed for low-dose daily oral outpatient dosing with a more predictable psilocin exposure profile than conventional psilocybin, initially targeting cluster headache, with co-development in PTSD, substance use disorder and generalized anxiety disorder.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
